sermorelin vs semaglutide for weight loss Injections Kirkland & Bellevue Sermorelin vs semaglutide: which peptide

Generation I Semaglutide GLP-1 only Peak Weight Loss 14.9% STEP 1 trial 68 weeks Receptor Coverage Single GLP-1 FDA Status Approved (Wegovy, 2021) FIRST PUBLISHED Wilding et al., NEJM 2021 Generation II Tirzepatide GLP-1 + GIP Peak Weight Loss 22.5% SURMOUNT-1 trial 72 weeks Receptor Coverage Dual GLP-1, GIP FDA Status Approved (Zepbound, 2023) First Published Jastreboff et al., NEJM 2022 Generation III Retatrutide GLP-1 + GIP + GCGR Peak Weight Loss 24.2% Phase 2 48 weeks (highest dose) Receptor Coverage Triple GLP-1, GIP, GCGR FDA Status Phase 3 (TRIUMPH program) First Published Jastreboff et al., NEJM 2023 -SELECTED LITERATURE Key Retatrutide research and clinical publications

it exists in clinical trials and as research-grade material

Conversely, others prefer morning administration to avoid nocturnal gastrointestinal discomfort that might disrupt sleep

Evaluation at 12 weeks: If a patient has not lost at least 3% of body weight by week 12 on the 7.5/46 mg dose, the prescriber will either titrate up to 11.25/69 mg for 14 days then 15/92 mg, or discontinue the medication entirely